Bolt Biotherapeutics, Inc. – NASDAQ:BOLT

Bolt Biotherapeutics stock price today

$4.85
+4.33
+836.29%
Financial Health
0
1
2
3
4
5
6
7
8
9

Bolt Biotherapeutics stock price monthly change

-30.87%
month

Bolt Biotherapeutics stock price quarterly change

-30.87%
quarter

Bolt Biotherapeutics stock price yearly change

-50.19%
year

Bolt Biotherapeutics key metrics

Market Cap
18.37M
Enterprise value
65.56M
P/E
-0.54
EV/Sales
11.44
EV/EBITDA
-0.76
Price/Sales
9.11
Price/Book
0.30
PEG ratio
-0.02
EPS
-1.66
Revenue
11.32M
EBITDA
-73.46M
Income
-63.02M
Revenue Q/Q
188.82%
Revenue Y/Y
67.96%
Profit margin
-1537.76%
Oper. margin
-1576.56%
Gross margin
48.94%
EBIT margin
-1576.56%
EBITDA margin
-648.71%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Bolt Biotherapeutics stock price history

Bolt Biotherapeutics stock forecast

Bolt Biotherapeutics financial statements

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT): Profit margin
Jun 2023 1.43M -18.05M -1260.08%
Sep 2023 2.52M -16.25M -643.08%
Dec 2023 2.08M -17.90M -857.01%
Mar 2024 5.27M -10.81M -204.99%
Bolt Biotherapeutics, Inc. (NASDAQ:BOLT): Analyst Estimates
Dec 2023 2.08M -17.90M -857.01%
Mar 2024 5.27M -10.81M -204.99%
Oct 2025 750K -11.42M -1522.74%
Dec 2025 750K -11.80M -1573.49%
  • Analysts Price target

  • Financials & Ratios estimates

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT): Debt to assets
Jun 2023 190696000 48.56M 25.47%
Sep 2023 175355000 47.09M 26.86%
Dec 2023 159784000 47.04M 29.44%
Mar 2024 142892000 38.73M 27.11%
Bolt Biotherapeutics, Inc. (NASDAQ:BOLT): Cash Flow
Jun 2023 -15.11M 13.58M 147K
Sep 2023 -16.74M 12.65M 0
Dec 2023 -14.26M 15.80M 106K
Mar 2024 -16.75M 10.20M 0

Bolt Biotherapeutics alternative data

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT): Employee count
Aug 2023 94
Sep 2023 94
Oct 2023 94
Nov 2023 94
Dec 2023 94
Jan 2024 94
Feb 2024 94
Mar 2024 100
Apr 2024 100
May 2024 100
Jun 2024 100
Jul 2024 100

Bolt Biotherapeutics other data

71.67% -0.68%
of BOLT is owned by hedge funds
26.72M -132.45K
shares is hold by hedge funds

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT): Insider trades (number of shares)
Period Buy Sel
Nov 2023 0 289454
Dec 2023 10000 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
QUINN WILLIAM P. officer: Chief Fi.. Common Stock 7,500 $0.95 $7,125
Purchase
QUINN WILLIAM P. officer: Chief Fi.. Common Stock 2,500 $0.78 $1,955
Sale
ENGLEMAN EDGAR director
Common Stock 108,145 $0.86 $92,788
Sale
ENGLEMAN EDGAR director
Common Stock 14,934 $0.86 $12,813
Sale
ENGLEMAN EDGAR director
Common Stock 22,674 $0.91 $20,543
Sale
ENGLEMAN EDGAR director
Common Stock 3,131 $0.91 $2,837
Sale
VIVO CAPITAL VIII, LLC 10 percent owner
Common Stock 1,707 $0.9 $1,536
Sale
VIVO CAPITAL VIII, LLC 10 percent owner
Common Stock 236 $0.9 $212
Sale
VIVO CAPITAL VIII, LLC 10 percent owner
Common Stock 1,457 $0.9 $1,311
Sale
ENGLEMAN EDGAR director
Common Stock 1,707 $0.9 $1,538
Monday, 11 November 2024
newsfilecorp.com
Thursday, 7 November 2024
globenewswire.com
Friday, 6 September 2024
accesswire.com
Thursday, 5 September 2024
accesswire.com
Wednesday, 4 September 2024
globenewswire.com
accesswire.com
Tuesday, 3 September 2024
prnewswire.com
accesswire.com
accesswire.com
prnewswire.com
Monday, 2 September 2024
businesswire.com
accesswire.com
globenewswire.com
accesswire.com
Sunday, 1 September 2024
accesswire.com
accesswire.com
accesswire.com
Saturday, 31 August 2024
prnewswire.com
accesswire.com
Friday, 30 August 2024
prnewswire.com
globenewswire.com
accesswire.com
accesswire.com
accesswire.com
Thursday, 29 August 2024
globenewswire.com
accesswire.com
accesswire.com
accesswire.com
Wednesday, 28 August 2024
accesswire.com
globenewswire.com
  • What's the price of Bolt Biotherapeutics stock today?

    One share of Bolt Biotherapeutics stock can currently be purchased for approximately $4.85.

  • When is Bolt Biotherapeutics's next earnings date?

    Unfortunately, Bolt Biotherapeutics's (BOLT) next earnings date is currently unknown.

  • Does Bolt Biotherapeutics pay dividends?

    No, Bolt Biotherapeutics does not pay dividends.

  • How much money does Bolt Biotherapeutics make?

    Bolt Biotherapeutics has a market capitalization of 18.37M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 37.48% to 7.88M US dollars.

  • What is Bolt Biotherapeutics's stock symbol?

    Bolt Biotherapeutics, Inc. is traded on the NASDAQ under the ticker symbol "BOLT".

  • What is Bolt Biotherapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Bolt Biotherapeutics?

    Shares of Bolt Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Bolt Biotherapeutics's key executives?

    Bolt Biotherapeutics's management team includes the following people:

    • Dr. Randall C. Schatzman Chief Executive Officer & Director(age: 70, pay: $706,050)
    • Dr. Edith A. Perez M.D. Chief Medical Officer(age: 68, pay: $607,490)
    • Mr. William P. Quinn Chief Financial Officer(age: 54, pay: $454,690)
    • Mr. Grant Yonehiro Chief Bus. Officer(age: 61, pay: $434,070)
    • Dr. David Dornan Ph.D. Chief Scientific Officer(age: 47, pay: $422,500)
  • How many employees does Bolt Biotherapeutics have?

    As Jul 2024, Bolt Biotherapeutics employs 100 workers.

  • When Bolt Biotherapeutics went public?

    Bolt Biotherapeutics, Inc. is publicly traded company for more then 4 years since IPO on 5 Feb 2021.

  • What is Bolt Biotherapeutics's official website?

    The official website for Bolt Biotherapeutics is boltbio.com.

  • Where are Bolt Biotherapeutics's headquarters?

    Bolt Biotherapeutics is headquartered at 900 Chesapeake Drive, Redwood City, CA.

  • How can i contact Bolt Biotherapeutics?

    Bolt Biotherapeutics's mailing address is 900 Chesapeake Drive, Redwood City, CA and company can be reached via phone at +65 06659295.

Bolt Biotherapeutics company profile:

Bolt Biotherapeutics, Inc.

boltbio.com
Exchange:

NASDAQ

Full time employees:

100

Industry:

Biotechnology

Sector:

Healthcare

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.

900 Chesapeake Drive
Redwood City, CA 94063

CIK: 0001641281
ISIN: US0977021049
CUSIP: 097702104